EIK1001 + pembrolizumab

EIK1001 + pembrolizumab is a combination of two investigational and approved drugs used in cancer immunotherapy clinical trials, specifically in advanced and metastatic solid tumors, notably non-small cell lung cancer (NSCLC). **EIK1001** is a Toll-like receptor 7/8 (TLR7/8) agonist that activates dendritic cells, thus stimulating both immune and inflammatory responses against tumor cells. **Pembrolizumab** is a fully human monoclonal antibody that targets the immune checkpoint protein programmed death receptor-1 (PD-1), blocking its interaction with PD-L1 and PD-L2 and thereby enhancing T-cell-mediated immune responses against cancer. When used together, EIK1001 provides an immune-stimulating pathway distinct from checkpoint inhibition, potentially improving antitumor activity beyond pembrolizumab monotherapy. Clinical studies indicate the combination is well-tolerated and shows preliminary efficacy across various tumor types, including patients heavily pretreated or with low/negative PD-L1 tumor expression[3][7][10].

Brand names

Keytruda

Other names

EIK1001 + Keytruda